StockNews.com Begins Coverage on Advaxis (OTCMKTS:ADXS)
StockNews.com Begins Coverage on Advaxis (OTCMKTS:ADXS)
StockNews.com assumed coverage on shares of Advaxis (OTCMKTS:ADXS – Get Rating) in a report published on Monday. The firm issued a sell rating on the biotechnology company's stock.
Advaxis Price Performance
Shares of Advaxis stock opened at $1.79 on Monday. The firm has a market cap of $3.25 million, a price-to-earnings ratio of -0.20 and a beta of 2.44. Advaxis has a 52-week low of $1.00 and a 52-week high of $11.18. The stock has a 50-day simple moving average of $1.73 and a 200-day simple moving average of $1.68.
Get Advaxis alerts:Advaxis Company Profile
(Get Rating)
Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.
Read More
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- META Platforms May See its Biggest Opening Yet for New Highs
- Penny Stock Vinco Ventures Could Be Big Winner
- Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
- Should You Park Some Capital with Casey's General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com承擔了對以下股票的報道Advaxis(OTCMKTS:ADXS-獲取評級)在週一發佈的一份報告中。該公司對這家生物技術公司的股票發佈了賣出評級。
Advaxis性價比
Advaxis的股票週一開盤報1.79美元。該公司的市值為325萬美元,本益比為-0.20倍,貝塔係數為2.44。Advaxis的52周低點為1.00美元,52周高位為11.18美元。該股的50日簡單移動均線切入位在1.73美元,200日簡單移動均線切入位在1.68美元。
到達前進軸警報:Advaxis公司簡介
(獲取評級)
Advaxis,Inc.是一家生物技術公司,從事癌症免疫療法的發現、開發和商業化。它管理的平臺技術利用減毒活的單核細胞增生性李斯特菌生物工程來分泌抗原或佐劑融合蛋白。該公司在臨床和臨床前開發的不同階段擁有四個專營權,即:HPV相關癌症、前列腺癌、新抗原治療和熱點突變治療。
閱讀更多內容
- 免費獲取StockNews.com關於Advaxis的研究報告(ADXS)
- Meta平臺可能迎來迄今最大的開盤創新高
- Penny Stock Vinco Ventures可能成為大贏家
- 晶片設計專家Synopsys是隱藏在眾目睽睽之下的寶石嗎?
- 你應該在凱西的百貨商店裡預留一些資本嗎?
- CrowdStrike股票:趁熱打鐵!
接受Advaxis Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Advaxis和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧